At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing, commercialized nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services. NorthStar is the only commercial U.S. producer of the important diagnostic imaging radioisotope molybdenum-99 (Mo-99). Our FDA-approved RadioGenix® System (technetium Tc 99m generator) uses U.S.-produced, non-uranium based Mo-99 as source material to generate technetium-99m (Tc-99m), used to assess heart disease and cancer for 40,000 U.S. patients daily. NorthStar continues to expand Mo-99 production capabilities to meet anticipated increased demand. Therapeutic radioisotopes are increasingly important options for cancer treatment, and NorthStar is expanding our industry-leading position in developing commercial-scale production technologies. We are poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225) and copper-67 (Cu-67), using first-in-kind and environmentally preferable, electron accelerator technology. We are advancing additional radiopharmaceuticals in our robust portfolio to help patients with serious disease. NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CMDO/CMO) unit will provide customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies advance their development and commercialization programs. At NorthStar, professional growth for our employees is a priority. Working with our cutting-edge technology offers a stimulating and rewarding environment for talented individuals who want to be part of our exciting and growing business. We are committed to ensuring that we provide fulfilling work experiences and valuable career development opportunities for our employees.